{"mainPropery":{"diseaseId":5243,"diseaseName":"Autosomal dominant optic atrophy plus syndrome","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/5243/autosomal-dominant-optic-atrophy-plus-syndrome","synonyms":["Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy","OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY","DOMINANT OPTIC ATROPHY PLUS SYNDROME","Treft-Sanborn-Carey syndrome","Optic atrophy - deafness- polyneuropathy - myopathy","Optic atrophy-deafness-polyneuropathy-myopathy syndrome"],"synonyms-with-source":[{"name":"Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy"},{"name":"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY","source":"OMIM"},{"name":"DOMINANT OPTIC ATROPHY PLUS SYNDROME","source":"OMIM"},{"name":"Treft-Sanborn-Carey syndrome","source":"Orphanet"},{"name":"Optic atrophy - deafness- polyneuropathy - myopathy","source":"OrphaData.Org"},{"name":"Optic atrophy-deafness-polyneuropathy-myopathy syndrome","source":"OrphaData.Org"}],"identifiers":[{"identifierType":"OMIM","identifierId":"125250"},{"identifierType":"ORPHANET","identifierId":"1215"},{"identifierType":"UMLS","identifierId":"C2931235"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":176,"resourceName":"United Mitochondrial Disease Foundation","abbreviation":"","address1":"8085 Saltsburg Road, Suite 201","address2":"","address3":"","address4":"","address5":"","city":"Pittsburgh","state":"PA","zip":"15239 ","country":"United States","phone":"+1-412-793-8077 ","tty":"","tollFree":"1-888-317-8633","fax":"+1-412-793-6477 ","email":"info@umdf.org","url":"https://www.umdf.org","freeText":""},{"resourceID":3421,"resourceName":"Autosomal Dominant Optic Atrophy Association","abbreviation":"","address1":"94 Bethel Court","address2":"","address3":"","address4":"","address5":"","city":"Port Matilda","state":"PA","zip":"16870","country":"","phone":"570-419-8799","tty":"","tollFree":"","fax":"","email":"lindsey.allen@adoaa.org","url":"http://www.adoaa.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/125250' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=%22Autosomal+dominant+optic+atrophy+plus+syndrome%22' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Autosomal dominant optic atrophy plus syndrome. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:125250' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":12509,"questionText":"What is autosomal dominant optic atrophy plus syndrome (ADOA plus)?","answerText":"<strong>Autosomal dominant optic atrophy plus syndrome (ADOA plus) </strong>is a rare syndrome that causes <a href=\"https://medlineplus.gov/visionimpairmentandblindness.html\">vision loss</a>, <a href=\"https://medlineplus.gov/ency/article/003044.htm\">hearing loss</a>, and symptoms affecting the muscles. The syndrome is associated with degeneration of the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a> (<a href=\"https://medlineplus.gov/ency/article/001622.htm\">optic atrophy</a>). The optic nerve sends signals about what the eyes are seeing to the brain. When there is optic nerve damage, it causes vision loss. Other symptoms of ADOA plus include <a href=\"https://www.asha.org/public/hearing/Sensorineural-Hearing-Loss/\" target=\"_blank\">sensorineural hearing loss</a> and symptoms affecting the muscles such as muscle pain and weakness.[14243]<br />\r\n<br />\r\nADOA plus is caused by changes (<a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutations</a><span>)</span> in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. The syndrome is inherited in an <a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a> manner. A diagnosis of ADOA plus is suspected when an eye exam finds degeneration of the optic nerve (optic atrophy). The diagnosis can be confirmed with a <a href=\"https://medlineplus.gov/ency/article/003924.htm\">muscle biopsy</a> and <a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">genetic testing</a> of the <em>OPA1</em> gene. Treatment options include visual and <a href=\"https://medlineplus.gov/hearingaids.html\">hearing aids</a>. Certain medications have been found to help improve vision loss in some people.[14243][7018]<br />","dateModified":"2018-01-10T16:36:00"},"basicQuestions":[{"questionId":12510,"questionText":"What are the signs and symptoms of autosomal dominant optic atrophy plus syndrome (ADOA plus)?","answerText":"Autosomal dominant optic atrophy plus syndrome (ADOA plus)<strong> </strong>is associated with <a href=\"https://medlineplus.gov/visionimpairmentandblindness.html\">vision loss</a>, <a href=\"https://medlineplus.gov/ency/article/003044.htm\">hearing loss</a>, and symptoms affecting the muscles. Vision loss is frequently the first symptom that develops in people with ADOA plus, and it typically begins in childhood. Hearing loss that is caused by damage to the nerves of the inner ear (<a href=\"https://www.asha.org/public/hearing/Sensorineural-Hearing-Loss/\" target=\"_blank\">sensorineural hearing loss</a>) typically develops during adolescence or young adulthood. &nbsp;Other symptoms of ADOA plus may develop in adulthood and include muscle weakness (<a href=\"https://medlineplus.gov/ency/article/003174.htm\">myopathy</a>), weakness of the eye muscles (<a href=\"https://www.healthline.com/health/ophthalmoplegia\">ophthalmoplegia</a>), trouble coordinating movements (<a href=\"https://medlineplus.gov/ency/article/003198.htm\">ataxia</a>), and pain and tingling in the arms and legs (<a href=\"https://medlineplus.gov/ency/article/000593.htm\">peripheral neuropathy</a>).[14243] <br />\r\n<br />\r\nIn general, the symptoms of ADOA plus are progressive. This means that symptoms of the syndrome may worsen over time. However, for some people with the syndrome, symptoms such as vision or hearing loss may stabilize. In rare cases, the symptoms of ADOA plus may progress to be similar to the symptoms of <a href=\"https://rarediseases.info.nih.gov/diseases/10255/multiple-sclerosis\">multiple sclerosis</a>.[14243]<br />\r\n<br />\r\nADOA plus is a syndrome that shows <a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">variable expressivity</a>. This means that people with the syndrome may have signs and symptoms that are different from each other, even among people in the same family. For example, some people with ADOA plus may only have vision loss, while others may also have symptoms such as muscle weakness or hearing loss.[14244][14245]","dateModified":"2018-01-10T16:49:00","resourceClassificationName":"Symptoms","references":[{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14244,"authors":"","articleTitle":"Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy","bookWebsiteJournalTitle":"Online Mendelian Inheritance in Man (OMIM)","date":"April 7, 2016","volume":"https://www.omim.org/entry/125250","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14245,"authors":"Skidd PM, Lessell S, and Cestari DM","articleTitle":"Autosomal dominant hereditary optic neuropathy (ADOA): a review of the genetics and clinical manifestations of ADOA and ADOA+","bookWebsiteJournalTitle":"Seminars in Ophthalmology","date":"September-November 2013","volume":"28(5-6)","pages":"422-426","url":"https://www.ncbi.nlm.nih.gov/pubmed/24138050","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12511,"questionText":"What causes autosomal dominant optic atrophy plus syndrome (ADOA plus)?","answerText":"Autosomal dominant optic atrophy plus syndrome (ADOA plus) is caused by <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutations</a> (changes) in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a>. This gene provides instructions to make a protein that is present in many different parts of the body including the <a href=\"https://medlineplus.gov/ency/article/002291.htm\">retina</a> (part of the eye), muscles, and <a href=\"https://medlineplus.gov/ency/imagepages/18125.htm\">nervous system</a>.[14245] The OPA1 protein is located in the <a href=\"https://www.umdf.org/what-is-mitochondrial-disease/\">mitochondria</a>. Mitochondria are the parts of the cell that provide energy, and the OPA1 protein helps regulate the changing shapes of the mitochondria, so that the mitochondria can do its many jobs inside the cell.[14243][14246] When there are changes in the <em>OPA1</em> gene, there is not enough protein working correctly to help maintain the mitochondria, especially in the eyes, muscles, and nervous system. Scientists believe these changes cause the signs and symptoms associated with ADOA plus.[14243]<br />\r\n<br />\r\nIn some cases, people with a mutation in the <em>OPA1</em> gene have a different disease called <a href=\"https://rarediseases.info.nih.gov/diseases/9890/optic-atrophy-1\" target=\"_blank\">optic atrophy type 1</a> that only causes vision loss without any other symptoms. It is not known exactly why some people with changes in <em>OPA1 </em>only have vision loss while others have additional symptoms, but it may be in part based on the location of the change in the <em>OPA1</em> gene.[14244][2835]&nbsp;&nbsp;<br />","dateModified":"2018-01-10T16:54:00","resourceClassificationName":"Cause","references":[{"referenceId":2835,"authors":"Delettre-Cribaillet C, Hamel CP, and Lenaers G","articleTitle":"Optic Atrophy Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"November 12, 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1248/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14244,"authors":"","articleTitle":"Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy","bookWebsiteJournalTitle":"Online Mendelian Inheritance in Man (OMIM)","date":"April 7, 2016","volume":"https://www.omim.org/entry/125250","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14245,"authors":"Skidd PM, Lessell S, and Cestari DM","articleTitle":"Autosomal dominant hereditary optic neuropathy (ADOA): a review of the genetics and clinical manifestations of ADOA and ADOA+","bookWebsiteJournalTitle":"Seminars in Ophthalmology","date":"September-November 2013","volume":"28(5-6)","pages":"422-426","url":"https://www.ncbi.nlm.nih.gov/pubmed/24138050","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14246,"authors":"Bonifert T, Karle KN, Tonagel F, Batra M, Wilhelm C, Theurer Y, Schoenfeld C, Kluba T, Kamenisch Y, Carelli V, Wolf J, Gonzalez MA, Speziani F, Schule R, Zuchner S, Schols L, Wissinger B, and Synofzik M","articleTitle":"Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier","bookWebsiteJournalTitle":"Brain","date":"August 2014","volume":"137(Pt. 8)","pages":"2164-2177","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24970096/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12512,"questionText":"How is autosomal dominant optic atrophy plus syndrome (ADOA plus) inherited?","answerText":"Autosomal dominant optic atrophy plus syndrome (ADOA plus) is inherited in an <a href=\"https://medlineplus.gov/ency/article/002049.htm\">autosomal dominant</a> manner.[14243] This means that people with ADOA plus have a disease-causing change in one copy of the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a><em> </em><a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> in every cell of their body. Of note, a disease-causing genetic change used to be called a <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation\">mutation</a>, but is now called a pathogenic variation on genetic testing reports. Most genes, including <em>OPA1</em>, come in pairs. We inherit one copy of each gene from our mother and the other from our father. When a person with ADOA plus has children, each child has a:<br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li>50% chance to have ADOA plus</li>\r\n    <li>50% chance not to have ADOA plus</li>\r\n</ul>\r\n<br />\r\nADOA plus shows features called <a href=\"https://ghr.nlm.nih.gov/primer/inheritance/penetranceexpressivity\">variable expressivity and reduced penetrance</a>.[14244][14245] Variable expressivity means that people with the syndrome may have signs and symptoms that are different from each other, even among people in the same family. Reduced penetrance means that, in some cases, people in a family with ADOA plus may inherit a disease-causing change in the <em>OPA1</em> gene without showing any signs or symptoms of the syndrome. However, anyone with a disease-causing change in the <em>OPA1</em> gene, whether they have symptoms or not, can pass on the genetic change to their children, and those children could have symptoms of ADOA plus.[14244][14245]<br />","dateModified":"2018-01-10T17:01:00","resourceClassificationName":"Inheritance","references":[{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14244,"authors":"","articleTitle":"Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia, And Neuropathy","bookWebsiteJournalTitle":"Online Mendelian Inheritance in Man (OMIM)","date":"April 7, 2016","volume":"https://www.omim.org/entry/125250","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14245,"authors":"Skidd PM, Lessell S, and Cestari DM","articleTitle":"Autosomal dominant hereditary optic neuropathy (ADOA): a review of the genetics and clinical manifestations of ADOA and ADOA+","bookWebsiteJournalTitle":"Seminars in Ophthalmology","date":"September-November 2013","volume":"28(5-6)","pages":"422-426","url":"https://www.ncbi.nlm.nih.gov/pubmed/24138050","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12513,"questionText":"How is autosomal dominant optic atrophy plus syndrome (ADOA plus) diagnosed?","answerText":"Autosomal dominant optic atrophy plus syndrome (ADOA plus) is typically suspected when a person has signs or symptoms consistent with the syndrome, such as evidence of degeneration of the <a href=\"https://medlineplus.gov/ency/imagepages/9708.htm\">optic nerve</a> (<a href=\"https://medlineplus.gov/ency/article/001622.htm\">optic atrophy</a>) on an eye exam. If ADOA plus is suspected, other tests may be ordered including:<br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li><a href=\"https://medlineplus.gov/ency/article/003929.htm\">Electromyography (EMG)</a></li>\r\n    <li><a href=\"https://medlineplus.gov/ency/article/003924.htm\">Muscle biopsy</a></li>\r\n    <li><a href=\"https://medlineplus.gov/ency/article/003791.htm\">Brain MRI</a></li>\r\n</ul>\r\n<a href=\"https://ghr.nlm.nih.gov/primer/testing/genetictesting\">Genetic testing</a> of the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a><em> </em><a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> may be ordered to confirm the diagnosis and to help identify other family members who are affected with the syndrome.[14243]<br />","dateModified":"2018-01-10T17:15:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12514,"questionText":"How might autosomal dominant optic atrophy plus syndrome (ADOA plus) be treated?","answerText":"Unfortunately, there is no cure for autosomal dominant optic atrophy plus syndrome (ADOA plus). Treatment options that may be recommended for people with ADOA plus  include:[14243]<br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li>Visual aids such as glasses and contact lenses</li>\r\n    <li><a href=\"https://medlineplus.gov/hearingaids.html\" target=\"_blank\">Hearing aids</a> or <a href=\"https://medlineplus.gov/ency/article/007203.htm\">cochlear implants</a></li>\r\n</ul>\r\nCurrently, there are no medications that are regularly used to relieve or reverse the symptoms associated with ADOA plus. In some clinical trials, people with a disease-causing genetic change in the <a href=\"https://ghr.nlm.nih.gov/gene/OPA1\"><em>OPA1</em></a> <a href=\"https://ghr.nlm.nih.gov/primer/basics/gene\">gene</a> have found some improvement in vision using a medication called idebenone.[14243][7018] However, this medication may not be appropriate for everyone with ADOA plus, and it may only be available through research studies.&nbsp;<br />","dateModified":"2018-01-10T17:17:00","resourceClassificationName":"Treatment","references":[{"referenceId":7018,"authors":"Barboni P. et al","articleTitle":"Idebenone treatment in patients with OPA1-mutant dominant optic atrophy","bookWebsiteJournalTitle":"Brain","date":"February 2013","volume":"136(Pt 2)","pages":"e231","url":"https://www.ncbi.nlm.nih.gov/pubmed/23388408","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":12515,"questionText":"What is the long-term outlook for people affected by autosomal dominant optic atrophy plus syndrome (ADOA plus)?","answerText":"In general, autosomal dominant optic atrophy plus syndrome (ADOA plus) is a progressive syndrome, meaning symptoms may continue to worsen over time.[14243] In some cases, symptoms of the syndrome such as <a href=\"https://medlineplus.gov/visionimpairmentandblindness.html\">vision</a> or <a href=\"https://medlineplus.gov/ency/article/003044.htm\">hearing loss</a> may stabilize. Because the different symptoms of ADOA plus may begin at different ages, it may be difficult to know if other symptoms of the disease will develop over time. In general, it is thought that the vision loss associated with ADOA plus is more severe than in individuals who have other types of autosomal dominant optic atrophy.[14243]&nbsp;<br />","dateModified":"2018-01-10T17:22:00","resourceClassificationName":"Prognosis","references":[{"referenceId":14243,"authors":"Milea D and Procaccio V","articleTitle":"Autosomal dominant optic atrophy plus syndrome","bookWebsiteJournalTitle":"Orphanet","date":"April 2015","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=1215","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[{"referenceId":8513,"authors":"Treft RL, Sanborn GE, Carey J, Swartz M, Crisp D, Wester DC & Creel D","articleTitle":"Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy. A new syndrome","bookWebsiteJournalTitle":"Ophthalmology","date":"August, 1984","volume":"91(8):","pages":"908-15.","url":"http://www.ncbi.nlm.nih.gov/pubmed/6493699","dateAccessed":"2015-03-16T00:00:00","authors2":"","placeOfPublication":"","publisher":""}],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13661,"phenoTypeName":"Impaired pain sensation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11337,"phenoTypeName":"Sensorineural hearing impairment","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9141,"phenoTypeName":"Color vision defect","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9404,"phenoTypeName":"Reduced tendon reflexes","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5614,"phenoTypeName":"Visual impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10117,"phenoTypeName":"Abnormality of visual evoked potentials","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14146,"phenoTypeName":"Decreased nerve conduction velocity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10498,"phenoTypeName":"Strabismus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9191,"phenoTypeName":"Abnormal amplitude of pattern reversal visual evoked potentials","percentRanges":"-"},{"phenoTypeId":1630,"phenoTypeName":"Abnormal auditory evoked potentials","percentRanges":"-"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":9186,"phenoTypeName":"Central scotoma","percentRanges":"-"},{"phenoTypeId":9166,"phenoTypeName":"Centrocecal scotoma","percentRanges":"-"},{"phenoTypeId":10140,"phenoTypeName":"Horizontal nystagmus","percentRanges":"-"},{"phenoTypeId":6239,"phenoTypeName":"Increased variability in muscle fiber diameter","percentRanges":"-"},{"phenoTypeId":14500,"phenoTypeName":"Myopathy","percentRanges":"-"},{"phenoTypeId":9185,"phenoTypeName":"Ophthalmoplegia","percentRanges":"-"},{"phenoTypeId":2230,"phenoTypeName":"Peripheral neuropathy","percentRanges":"-"},{"phenoTypeId":8730,"phenoTypeName":"Polyneuropathy","percentRanges":"-"},{"phenoTypeId":5255,"phenoTypeName":"Progressive","percentRanges":"-"},{"phenoTypeId":11338,"phenoTypeName":"Progressive sensorineural hearing impairment","percentRanges":"-"},{"phenoTypeId":5615,"phenoTypeName":"Ptosis","percentRanges":"-"},{"phenoTypeId":10114,"phenoTypeName":"Red-green dyschromatopsia","percentRanges":"-"},{"phenoTypeId":10515,"phenoTypeName":"Reduced visual acuity","percentRanges":"-"},{"phenoTypeId":9142,"phenoTypeName":"Tritanomaly","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Autosomal_dominant_optic_atrophy_plus_syndrome"}